Advertisement

Neurocritical Care

, Volume 8, Issue 2, pp 301–307 | Cite as

S100 as a Marker of Acute Brain Ischemia: A Systematic Review

  • David L. Nash
  • M. Fernanda Bellolio
  • Latha G. SteadEmail author
Review Article

Abstract

Background

Studies show S100 as a possible acute ischemic stroke (AIS) marker.

Objectives

Determine (1) whether S100 serum concentrations correlate with stroke symptom onset, infarction volume, stroke severity, functional outcome, or length of hospital stay; (2) whether S100 serial measurements are useful markers for ongoing brain ischemia, and (3) whether S100 levels at various time intervals are higher in AIS patients than controls.

Methods

Literature was searched using OVID and MEDLINE from January 1950 to February 2007, and all relevant reports were included.

Results

Eighteen studies (1,643 patients) satisfied entry criteria. S100 peaks from symptom onset between 24 and 120 h with significantly raised values measured from 0 to 120 h. Higher S100 values indicated significantly larger infarction volumes, more severe strokes, and worse functional outcome. There was a significant difference in S100 levels between AIS patients and controls.

Conclusion

Peak values after stroke onset varied. S100 was significantly increased after stroke onset, and correlates with infarct volume, stroke severity, and functional outcome, and was a possible marker for ongoing ischemia. Its serum concentration during acute stroke is a useful marker of infarct size and long-term clinical outcome.

Keywords

Serum markers S100 Acute brain ischemia Systematic review 

References

(*) Not included studies

  1. 1.
    Abraha HD, Butterworth RJ, Bath PM, Wassif WS, Garthwaite J, Sherwood RA. Serum S-100 protein, relationship to clinical outcome in acute stroke. Ann Clin Biochem 1997;34:366–70.PubMedGoogle Scholar
  2. 2.
    *Kanner AA, Marchi N, Fazio V, et al. Serum S100B: a noninvasive marker of blood-brain barrier function and brain lesions. Cancer 2003;97:2806–13.PubMedCrossRefGoogle Scholar
  3. 3.
    Büttner T, Weyers S, Postert T, Sprengelmeyer R, Kuhn W. S-100 protein: serum marker of focal brain damage after ischemic territorial MCA infarction. Stroke 1997;28:1961–5.PubMedGoogle Scholar
  4. 4.
    *Stroick M, Fatar M, Ragoschke-Schumm A, Fassbender K, Bertsch T, Hennerici MG. Protein S-100B—a prognostic marker for cerebral damage. Curr Med Chem 2006;13:3053–60.PubMedCrossRefGoogle Scholar
  5. 5.
    *Korfias S, Stranjalis G, Papadimitriou A, et al. Serum S-100B protein as a biochemical marker of brain injury: a review of current concepts. Curr Med Chem 2006;13:3719–31.PubMedCrossRefGoogle Scholar
  6. 6.
    *Di Legge S, Di Piero V, Di Stani F, et al. Carotid endarterectomy and gliofibrillar S100b protein release. Neurol Sci 2003;24:351–6.PubMedCrossRefGoogle Scholar
  7. 7.
    *Westaby S, Johnsson P, Parry AJ, et al. Serum S100 protein: a potential marker for cerebral events during cardiopulmonary bypass. Ann Thorac Surg 1996;61:88–92.PubMedCrossRefGoogle Scholar
  8. 8.
    *Georgiadis D, Berger A, Kowatschev E, et al. Predictive value of S-100beta and neuron-specific enolase serum levels for adverse neurologic outcome after cardiac surgery. J Thorac Cardiovasc Surg 2000;119(1):138–47.PubMedCrossRefGoogle Scholar
  9. 9.
    *Ishida K, Gohara T, Kawata R, Ohtake K, Morimoto Y, Sakabe T. Are serum S100B proteins and neuron-specific enolase predictors of cerebral damage in cardiovascular surgery? J Cardiothorac Vasc Anesth 2003;17:4–9.PubMedCrossRefGoogle Scholar
  10. 10.
    *Shirasaki Y, Edo N, Sato T. Serum S-100b protein as a biomarker for the assessment of neuroprotectants. Brain Res 2004;1021:159–66.PubMedCrossRefGoogle Scholar
  11. 11.
    *Wong C, Bonser RS. Serum S-100 protein in stroke and cardiac surgery. Stroke 1998;29:2446–7.Google Scholar
  12. 12.
    *Butterworth RJ, Sherwood RA, Bath PM. Serum S-100 protein in acute stroke. Stroke 1998;29:730.PubMedGoogle Scholar
  13. 13.
    Reynolds MA, Kirchick HJ, Dahlen JR, et al. Early biomarkers of stroke. Clin Chem 2003;49:1733–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Lynch JR, Blessing R, White WD, Grocott HP, Newman MF, Laskowitz DT. Novel diagnostic test for acute stroke. Stroke 2004;35:57–63.PubMedCrossRefGoogle Scholar
  15. 15.
    Wunderlich MT, Wallesch CW, Goertler M. Release of neurobiochemical markers if brain damage is related to the neurovascular status on admission and the site of arterial occlusion in acute ischemic stroke. J Neurol Sci 2004;227:49–53.PubMedCrossRefGoogle Scholar
  16. 16.
    Foerch C, Singer OC, Neumann-Haefelin T, du Mesnil de Rochemont R, Steinmetz H, Sitzer M. Evaluation of Serum S100B as a surrogate marker for long-term outcome and infarct volume in acute middle cerebral artery infarction. Arch Neurol 2005;62:1130–4.PubMedCrossRefGoogle Scholar
  17. 17.
    Foerch C, Otto B, Singer OC, et al. Serum S100B predicts a malignant course of infarction in patients with acute middle cerebral artery occlusion. Stroke 2004;35:2160–4.PubMedCrossRefGoogle Scholar
  18. 18.
    *Foerch C, Wunderlich MT, Dvorak F, et al. Elevated serum S100B levels indicate a higher risk of hemorrhagic transformation after thrombolytic therapy in acute stroke. Stroke 2007;38:2491–5.PubMedCrossRefGoogle Scholar
  19. 19.
    Missler U, Wiesmann M, Friedrich C, Kaps M. S-100 protein and neuron-specific enolase concentrations in blood as indicators of infarction volume and prognosis in acute ischemic stroke. Stroke 1997;28:1956–60.PubMedGoogle Scholar
  20. 20.
    Kim JS, Yoon SS, Kim YH, Ryu JS. Serial measurement of interleukin-6, transforming growth factor-β, and S-100 protein in patients with acute stroke. Stroke 1996;27:1553–7.PubMedGoogle Scholar
  21. 21.
    Mizukoshi G, Katsura K, Katayama Y. Urinary 8-hydroxy-2′-deoxyguanosine and serum S100B in acute cardioembolic stroke patients. Neurol Res 2005;27:644–6.PubMedCrossRefGoogle Scholar
  22. 22.
    Jauch EC, Lindsell C, Broderick J, Fagan SC, Tilley BC, Levine SR, NINDS rt-PA Stroke Study Group. Association of serial biochemical markers with acute ischemic stroke: the national institute of neurological disorders and stroke recombinant tissue plasminogen activator stroke study. Stroke 2006;37:2508–13.PubMedCrossRefGoogle Scholar
  23. 23.
    Foerch C, du Mesnil de Rochemont R, Singer O, Neumann-Haefelin T, et al. S100B as a surrogate marker for successful clot lysis in hyperacute middle cerebral artery occlusion. J Neurol Neurosurg Psychiatry 2003;74:322–5.PubMedCrossRefGoogle Scholar
  24. 24.
    Bertsch T, Casarin W, Kretschmar M, et al. Protein S-100B: a serum marker for ischemic and infectious injury of cerebral tissue. Clin Chem Lab Med 2001;39:319–23.PubMedCrossRefGoogle Scholar
  25. 25.
    Fassbender K, Schmidt R, Schreiner A, et al. Leakage of brain-originated proteins in peripheral blood: temporal profile and diagnostic value in early ischemic stroke. J Neurol Sci 1997;148:101–5.PubMedCrossRefGoogle Scholar
  26. 26.
    Jönsson H, Johnsson P, Birch-Iensen M, Alling C, Westaby S, Blomquist S. S100B as a predictor of size and outcome of stroke after cardiac surgery. Ann Thorac Surg 2001;71:1433–7.PubMedCrossRefGoogle Scholar
  27. 27.
    Aurell A, Rosengren LE, Karlsson B, Olsson JE, Zbornikova V, Haglid KG. Determination of S-100 and glial fibrillary acidic protein concentrations in cerebrospinal fluid after brain infarction. Stroke 1991;22:1254–8.PubMedGoogle Scholar
  28. 28.
    Persson L, Hardenmark HG, Gustafsson J, et al. S-100 protein and neuron-specific enolase in cerebrospinal fluid and serum: markers of cell damage in human central nervous system. Stroke 1987;18:911–8.PubMedGoogle Scholar
  29. 29.
    Hill MD, Jackowski G, Bayer N, Lawrence M, Jaeschke R. Biochemical markers in acute ischemic stroke. CMAJ 2000;162:1139–40.PubMedGoogle Scholar

Copyright information

© Humana Press Inc. 2007

Authors and Affiliations

  • David L. Nash
    • 1
  • M. Fernanda Bellolio
    • 1
  • Latha G. Stead
    • 1
    Email author
  1. 1.Mayo Clinic College of MedicineRochesterUSA

Personalised recommendations